KANGSTEM BIOTECH CO., LTD.
A stem cell therapeutics company developing umbilical cord blood-derived treatments for atopic dermatitis, rheumatoid arthritis, and osteoarthritis.
As of 2026-10-09, KANGSTEM BIOTECH CO., LTD. has 30 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2010 and listed on KOSDAQ in 2015, KangStem Biotech develops and manufactures stem cell therapeutics. Based on its technology for high-purity isolation and mass culture of multipotent stem cells derived from human umbilical cord blood, its pipeline includes PURESTEM-AD (atopic dermatitis), PURESTEM-RA (rheumatoid arthritis), and OSCA (osteoarthritis, formerly PURESTEM-OA Kit). It also sells stem cell culture medium-based cosmetics and is developing exosome-based treatments for wounds/burns, pneumonia, and hair loss. Its bio-pharma division discontinued operations in the prior period, and its non-clinical testing division was deconsolidated following the sale of its stake in HLB Biocode (formerly Croen).
Products & technology
- GD stem cell culture medium cosmeticsCosmetics
- BIO stem cell culture medium-based functional shampooFunctional shampoo
Clinical trials
data.go.kr22 MFDS clinical trial authorisations · 2013–2025 (Extension 6 · Phase 1 6 · Phase 1/2a 5 · Phase 2b 2 · Phase 3 2)
- Extension퓨어스템-오에이 키트 주(FURESTEM-OA Kit Inj.)2025-12-10
7 trial sites
- Phase 2b퓨어스템-알에이주(FURESTEM-RA Inj.)2023-09-27
1 trial site
- Phase 1/2a퓨어스템-오에이 키트 주(FURESTEM-OA Kit Inj.)2022-11-15
7 trial sites
- Phase 3퓨어스템-에이디 주(FURESTEM-AD Inj.)2021-05-06
12 trial sites
- Extension퓨어스템-에이디 주(FURESTEM-AD Inj.)2019-07-15
2 trial sites
- Phase 1/2a퓨어스템-에이디 주(FURESTEM-AD Inj.)2019-07-08
2 trial sites
- Extension퓨어스템-알에이주(FURESTEM-RA Inj.)2019-04-05
7 trial sites
- Extension퓨어스템-에이디 주(FURESTEM-AD Inj.)2018-11-15
10 trial sites
- Phase 1동종제대혈유래중간엽줄기세포3주(hUCB-MSC3 Inj.)2018-05-14
1 trial site
- Phase 1/2a퓨어스템-알에이주(FURESTEM-RA Inj.)2018-02-19
7 trial sites
- Phase 3퓨어스템-에이디 주(FURESTEM-AD Inj.)2017-12-04
10 trial sites
- Phase 1동종제대혈유래중간엽줄기세포4주(hUCB-MSC4 Inj.)2017-10-10
1 trial site
Show 10 more
- Extension퓨어스템-에이디 주(FURESTEM-AD Inj.)2016-12-14
11 trial sites
- Phase 1동종제대혈유래중간엽줄기세포3주(hUCB-MSC3 Inj.)2016-10-17
1 trial site
- Phase 2b퓨어스템-에이디 주(FURESTEM-AD Inj.)2016-07-14
6 trial sites
- Extension퓨어스템-알에이주(FURESTEM-RA Inj.)2016-05-09
1 trial site
- Phase 1/2a퓨어스템-에이디 주(FURESTEM-AD Inj.)2016-04-18
1 trial site
- Phase 1퓨어스템-시디주(FURESTEM-CD Inj.)2015-08-10
1 trial site
- Phase 1퓨어스템-시디주(FURESTEM-CD Inj.)2014-12-31
1 trial site
- Phase 1퓨어스템-알에이주(FURESTEM-RA Inj.)2014-05-28
1 trial site
- Phase 1/2a퓨어스템-시디주(FURESTEM-CD Inj.)2013-06-10
4 trial sites
- Phase 1/2퓨어스템-에이디 주(FURESTEM-AD Inj.)2013-01-28
1 trial site
R&D and key agreements
Source: DART corporate disclosure퓨어스템-에이디 주 · 아토피피부염 · Umbilical cord blood-derived stem cell therapy pipeline
퓨어스템-알에이 주 · 류마티스관절염 · Umbilical cord blood-derived stem cell therapy pipeline
오스카(OSCA) · 골관절염 · Formerly named PURESTEM-OA Kit
창상(화상)치료제 · 창상, 화상 · Exosome-based therapeutics pipeline
폐렴치료제 · 폐렴 · Exosome-based therapeutics pipeline
탈모치료제 · 탈모 · Exosome-based therapeutics pipeline
Key disclosures
KRX KIND via OpenDARTShow 10 more events
Publications
PubMed · affiliation-matched- Vascularized human skin assembloids model compartmental skin organization and immune responsiveness in vitro.
Experimental & molecular medicine · 2026-10 · Kim MJ, Lee S, Kang KS
- Long-term safety of intravenous human umbilical cord blood-derived mesenchymal stem cell therapy in rheumatoid arthritis: a 5-year follow-up study.
Stem cells translational medicine · 2026-07 · Park EH, Kim MJ, Kang KS 외 1
- First-in-human and multicenter phase I study of OSCA therapy for knee osteoarthritis.
Experimental & molecular medicine · 2026-05 · Suh DK, Lee SH, Bae Y 외 7
- Lung Microphysiological System Validates Novel Cell Therapy for Acute Respiratory Distress Syndrome.
Advanced biology · 2026-01 · Kim B, Kim SH, Kim J 외 9
- Primed Mesenchymal Stem Cells by IFN-γ and IL-1β Ameliorate Acute Respiratory Distress Syndrome through Enhancing Homing Effect and Immunomodulation.
Biomolecules & therapeutics · 2025-03 · Kong T, Seo SK, Han YS 외 6
- Therapeutic effect of long-interval repeated subcutaneous administration of canine amniotic membrane-derived mesenchymal stem cells in atopic dermatitis mouse model.
BMC veterinary research · 2025-02 · Kim M, Kong D, Kim NG 외 9
- TGFβ2-Driven Ferritin Degradation and Subsequent Ferroptosis Underlie Salivary Gland Dysfunction in Postmenopausal Conditions.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024-12 · Oh SJ, Shin YY, Ahn JS 외 15
- Sustained release of stem cell secretome from nano-villi chitosan microspheres for effective treatment of atopic dermatitis.
International journal of biological macromolecules · 2024-10 · Oh SJ, Nguyen TT, Seo Y 외 8
- Guidelines for Manufacturing and Application of Organoids: Skin.
International journal of stem cells · 2024-05 · Lee S, Rim YA, Kim J 외 5
- Modeling of solar UV-induced photodamage on the hair follicles in human skin organoids.
Journal of tissue engineering · 2024-01 · Kim MJ, Ahn HJ, Kong D 외 3
Show 20 more publications
- Canine amniotic membrane-derived mesenchymal stem cells ameliorate atopic dermatitis through regeneration and immunomodulation.
Veterinary research communications · 2023-12 · Kim MS, Kong D, Han M 외 4
- Association of potentially inappropriate medications and need for long-term care among older adults: a matched cohort study.
BMC geriatrics · 2022-12 · Jang S, Kang HJ, Kim Y 외 1
- Wnt-activating human skin organoid model of atopic dermatitis induced by Staphylococcus aureus and its protective effects by Cutibacterium acnes.
iScience · 2022-10 · Jung SY, You HJ, Kim MJ 외 3
- Immunomodulatory Effect of Epidermal Growth Factor Secreted by Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells on Atopic Dermatitis.
International journal of stem cells · 2022-08 · Jung N, Kong T, Yu Y 외 6
- Valproic Acid-Induced CCN1 Promotes Osteogenic Differentiation by Increasing CCN1 Protein Stability through HDAC1 Inhibition in Tonsil-Derived Mesenchymal Stem Cells.
Cells · 2022-02 · Yu Y, Oh SY, Kim HY 외 3
- Combined Mesenchymal Stem Cells and Cartilage Acellular Matrix Injection Therapy for Osteoarthritis in Goats.
Tissue engineering and regenerative medicine · 2022-02 · Kim M, Ahn J, Lee J 외 4
- LC-MS/MS-based serum proteomics reveals a distinctive signature in a rheumatoid arthritis mouse model after treatment with mesenchymal stem cells.
PloS one · 2022-01 · Jung N, Park S, Kong T 외 4
- Non-clinical assessment of cell therapy products: the perspective from five Asian countries/regions based on regulatory guidelines and the underpinning rationales.
Cytotherapy · 2021-10 · Yoneda T, Choi BH, Gupta PK 외 19
- Pimecrolimus interferes the therapeutic efficacy of human mesenchymal stem cells in atopic dermatitis by regulating NFAT-COX2 signaling.
Stem cell research & therapy · 2021-08 · Shin N, Jung N, Lee SE 외 7
- Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients.
JCI insight · 2021-01 · Lee SE, Lee SJ, Kim SE 외 4
- Effects of conditioned media from human umbilical cord blood-derived mesenchymal stem cells in the skin immune response.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2020-11 · Kim YJ, Ahn HJ, Lee SH 외 2
- TGF-β secreted by human umbilical cord blood-derived mesenchymal stem cells ameliorates atopic dermatitis by inhibiting secretion of TNF-α and IgE.
Stem cells (Dayton, Ohio) · 2020-07 · Park HH, Lee S, Yu Y 외 5
- Preconditioning with interleukin-1 beta and interferon-gamma enhances the efficacy of human umbilical cord blood-derived mesenchymal stem cells-based therapy via enhancing prostaglandin E2 secretion and indoleamine 2,3-dioxygenase activity in dextran sulfate sodium-induced colitis.
Journal of tissue engineering and regenerative medicine · 2019-10 · Yu Y, Yoo SM, Park HH 외 6
- Therapeutic effect of long-interval repeated intravenous administration of human umbilical cord blood-derived mesenchymal stem cells in DBA/1 mice with collagen-induced arthritis.
Journal of tissue engineering and regenerative medicine · 2019-07 · Yu Y, Yoon KA, Kang TW 외 7
- Interferon-γ-mediated secretion of tryptophanyl-tRNA synthetases has a role in protection of human umbilical cord blood-derived mesenchymal stem cells against experimental colitis.
BMB reports · 2019-05 · Kang I, Lee BC, Lee JY 외 5
- Human umbilical cord blood plasma alleviates age-related olfactory dysfunction by attenuating peripheral TNF-α expression.
BMB reports · 2019-04 · Lee BC, Kang I, Lee SE 외 5
- Far-Infrared Irradiation Inhibits Adipogenic Differentiation and Stimulates Osteogenic Differentiation of Human Tonsil-Derived Mesenchymal Stem Cells: Role of Protein Phosphatase 2B.
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2019-01 · Kim HY, Yu Y, Oh SY 외 5
- Conditioned media from human umbilical cord blood-derived mesenchymal stem cells stimulate rejuvenation function in human skin.
Biochemistry and biophysics reports · 2018-12 · Kim YJ, Seo DH, Lee SH 외 6
- Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase Ia Clinical Trial.
Stem cells translational medicine · 2018-09 · Park EH, Lim HS, Lee S 외 4
- Exosomes derived from human umbilical cord blood mesenchymal stem cells stimulates rejuvenation of human skin.
Biochemical and biophysical research communications · 2017-11 · Kim YJ, Yoo SM, Park HH 외 5
Patents
KIPRIS · applicant-matchedPublished · 2026-04 · Application 1020260068654
PCT · Published · 2025-12 · Application PCT/KR2025/020293
Published · 2025-12 · Application 1020250187411
PCT · Published · 2025-11 · Application PCT/KR2025/020171
Published · 2025-11 · Application 1020250183371
US · Published · 2025-06 · Application 19225491
US · Published · 2025-02 · Application 19056005
PCT · Published · 2025-01 · Application PCT/KR2025/001431
Published · 2025-01 · Application 1020250011652
Published · 2024-11 · Application 1020240157401
Show 139 more patents
PCT · Published · 2024-11 · Application PCT/KR2024/017560
EP · Published · 2024-10 · Application 24877509.0
US · Published · 2024-10 · Application 18870406
PCT · Published · 2024-10 · Application PCT/KR2024/015315
Published · 2024-10 · Application 1020240134730
Registered · 2024-09 · Application 1020240124789
Registered · 2024-07 · Application 1020240087171
Published · 2024-05 · Application 1020240061919
Registered · 2024-03 · Application 1020240038549
EP · Published · 2024-03 · Application 24771229.2
PCT · Published · 2024-03 · Application PCT/KR2024/003368
Published · 2024-03 · Application 1020240037009
EP · Published · 2023-12 · Application 23907848.8
Published · 2023-12 · Application 1020230189178
PCT · Published · 2023-12 · Application PCT/KR2023/021362
PCT · Published · 2023-12 · Application PCT/KR2023/021104
Registered · 2023-10 · Application 1020230135187
US · Published · 2023-06 · Application 18209857
- METHOD FOR PREPARING INJECTABLE INJECTION COMPOSITION DERIVED FROM ANIMAL CARTILAGE, AND USE THEREOF
US · Published · 2023-06 · Application 18333812
Registered · 2023-04 · Application 1020230047013
EP · Published · 2023-02 · Application 23760433.5
US · Published · 2023-02 · Application 18841119
US · Published · 2023-02 · Application 18841101
Published · 2023-02 · Application 1020230026245
EP · Published · 2023-02 · Application 23760434.3
PCT · Published · 2023-02 · Application PCT/KR2023/002742
PCT · Published · 2023-02 · Application PCT/KR2023/002743
Rejected · 2023-02 · Application 1020230026244
US · Published · 2022-12 · Application 19141126
US · Published · 2022-08 · Application 18683442
EP · Published · 2022-08 · Application 22858806.7
PCT · Published · 2022-08 · Application PCT/KR2022/012435
Registered · 2022-08 · Application 1020220104164
US · Published · 2022-06 · Application 18574055
US · Published · 2022-06 · Application 18574046
US · Published · 2022-06 · Application 18574056
US · Published · 2022-06 · Application 18574050
EP · Published · 2022-06 · Application 22828694.4
EP · Published · 2022-06 · Application 22828695.1
EP · Published · 2022-06 · Application 22828696.9
EP · Published · 2022-06 · Application 22828697.7
PCT · Published · 2022-06 · Application PCT/KR2022/008715
PCT · Published · 2022-06 · Application PCT/KR2022/008718
PCT · Published · 2022-06 · Application PCT/KR2022/008714
PCT · Published · 2022-06 · Application PCT/KR2022/008719
- METHOD FOR PREPARING INJECTABLE INJECTION COMPOSITION DERIVED FROM ANIMAL CARTILAGE, AND USE THEREOF
US · Published · 2021-11 · Application 18044813
EP · Published · 2021-11 · Application 23183127.2
- METHOD FOR PREPARING INJECTABLE INJECTION COMPOSITION DERIVED FROM ANIMAL CARTILAGE, AND USE THEREOF
EP · Published · 2021-11 · Application 21898670.1
- METHOD FOR PREPARING INJECTABLE INJECTION COMPOSITION DERIVED FROM ANIMAL CARTILAGE, AND USE THEREOF
PCT · Published · 2021-11 · Application PCT/KR2021/017617
Registered · 2021-11 · Application 1020210165676
Registered · 2021-11 · Application 1020210151328
Registered · 2021-11 · Application 1020210151329
Registered · 2021-11 · Application 1020210151330
US · Published · 2021-10 · Application 18249560
EP · Published · 2021-10 · Application 21883286.3
PCT · Published · 2021-10 · Application PCT/KR2021/014810
Registered · 2021-10 · Application 1020210140422
CN · Published · 2021-07 · Application 202180056717.6
Registered · 2021-07 · Application 1020210098641
US · Published · 2021-07 · Application 18040448
EP · Registered · 2021-07 · Application 21853077.2
PCT · Published · 2021-07 · Application PCT/KR2021/009732
Registered · 2021-07 · Application 1020210098642
Registered · 2021-07 · Application 1020210098640
Rejected · 2021-06 · Application 1020210082930
US · Published · 2021-01 · Application 17156476
EP · Published · 2021-01 · Application 21745031.1
PCT · Published · 2021-01 · Application PCT/KR2021/000942
Registered · 2021-01 · Application 1020210009773
Rejected · 2020-12 · Application 1020200176757
US · Published · 2020-12 · Application 17786015
EP · Published · 2020-12 · Application 20902522.0
PCT · Published · 2020-12 · Application PCT/KR2020/018485
Rejected · 2020-11 · Application 1020200150913
Rejected · 2020-01 · Application 1020200007337
Rejected · 2019-12 · Application 1020190175691
PCT · Published · 2019-11 · Application PCT/KR2019/016796
Rejected · 2019-07 · Application 1020190089087
EP · Published · 2019-05 · Application 19812038.8
US · Published · 2019-05 · Application 17059634
Registered · 2019-05 · Application 1020190064122
PCT · Published · 2019-05 · Application PCT/KR2019/006536
Withdrawn · 2019-05 · Application 1020190063442
PCT · Published · 2019-05 · Application PCT/KR2019/005566
Withdrawn · 2019-03 · Application 1020190027136
Registered · 2018-10 · Application 1020180130162
Rejected · 2018-10 · Application 1020180122818
Registered · 2018-05 · Application 1020180053363
Registered · 2017-09 · Application 1020170120585
Rejected · 2017-07 · Application 1020170092809
CN · Published · 2017-07 · Application 201780053687.7
EP · Registered · 2017-07 · Application 17824497.6
US · Registered · 2017-07 · Application 16315377
PCT · Published · 2017-07 · Application PCT/KR2017/007077
Registered · 2017-07 · Application 1020170085032
PCT · Published · 2017-05 · Application PCT/KR2017/005481
CN · Published · 2017-01 · Application 201780013787.7
US · Published · 2017-01 · Application 16069540
PCT · Published · 2017-01 · Application PCT/KR2017/000420
Rejected · 2017-01 · Application 1020170005480
CN · Published · 2016-12 · Application 201680082451.1
US · Published · 2016-12 · Application 16075262
PCT · Published · 2016-12 · Application PCT/KR2016/014138
CN · Published · 2016-09 · Application 201680066523.3
EP · Published · 2016-09 · Application 16846918.7
US · Registered · 2016-09 · Application 15760106
PCT · Published · 2016-09 · Application PCT/KR2016/010414
Registered · 2016-09 · Application 1020160119281
Registered · 2016-05 · Application 1020160064329
Registered · 2016-02 · Application 1020160014051
Registered · 2015-10 · Application 1020150150366
PCT · Published · 2015-09 · Application PCT/KR2015/010253
Rejected · 2015-09 · Application 1020150136755
Registered · 2015-09 · Application 1020150135122
PCT · Published · 2015-09 · Application PCT/KR2015/010065
Registered · 2014-10 · Application 1020140136410
Registered · 2014-10 · Application 1020140136031
Registered · 2014-10 · Application 1020140136150
Rejected · 2014-09 · Application 1020140120912
CN · Published · 2014-04 · Application 201480032201.8
EP · Registered · 2014-04 · Application 14779347.5
US · Registered · 2014-04 · Application 14782340
Registered · 2014-04 · Application 1020140040800
Registered · 2014-03 · Application 1020140026555
Rejected · 2014-01 · Application 1020140009917
Registered · 2013-02 · Application 1020130018397
Rejected · 2012-12 · Application 1020120141334
Registered · 2012-10 · Application 1020120118708
Withdrawn · 2012-01 · Application 1020120008588
Expired · 2011-11 · Application 1020110122548
Withdrawn · 2011-09 · Application 1020110091746
Registered · 2011-09 · Application 1020110090944
Rejected · 2011-09 · Application 1020110090423
Registered · 2011-08 · Application 1020110082687
Registered · 2011-03 · Application 1020110029908
Expired · 2011-02 · Application 1020110014808
Rejected · 2011-02 · Application 1020110014817
Expired · 2011-01 · Application 1020127016665
Registered · 2009-04 · Application 1020090032575
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIOAI-SearchBot47
- AnthropicClaudeBot2
- MicrosoftBingbot1
- PerplexityPerplexityBot1
- GoogleGoogleOther1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for KANGSTEM BIOTECH CO., LTD. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition